First Horizon Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $479K | Sell |
3,430
-95
| -3% | -$13.3K | 0.01% | 362 |
|
|
2025
Q1 | $518K | Buy |
3,525
+588
| +20% | +$85.1K | 0.01% | 330 |
|
|
2024
Q4 | $385K | Buy |
2,937
+208
| +8% | +$29.1K | 0.01% | 384 |
|
|
2024
Q3 | $425K | Buy |
2,729
+590
| +28% | +$95.2K | 0.01% | 375 |
|
|
2024
Q2 | $334K | Buy |
2,139
+1,421
| +198% | +$214K | 0.01% | 410 |
|
|
2024
Q1 | $97.3K | Sell |
718
-35
| -5% | -$4.63K | ﹤0.01% | 700 |
|
|
2023
Q4 | $101K | Sell |
753
-151
| -17% | -$19.6K | ﹤0.01% | 660 |
|
|
2023
Q3 | $122K | Sell |
904
-62
| -6% | -$8.47K | ﹤0.01% | 570 |
|
|
2023
Q2 | $138K | Sell |
966
-4
| -0.4% | -$589 | ﹤0.01% | 558 |
|
|
2023
Q1 | $135K | Buy |
970
+159
| +20% | +$21.4K | ﹤0.01% | 557 |
|
|
2022
Q4 | $110K | Buy |
811
+109
| +16% | +$13.7K | ﹤0.01% | 589 |
|
|
2022
Q3 | $76K | Buy |
702
+36
| +5% | +$4.57K | ﹤0.01% | 691 |
|
|
2022
Q2 | $88K | Buy |
666
+60
| +10% | +$7.87K | ﹤0.01% | 728 |
|
|
2022
Q1 | $80K | Sell |
606
-109
| -15% | -$13.1K | ﹤0.01% | 527 |
|
|
2021
Q4 | $82K | Sell |
715
-60
| -8% | -$7.06K | ﹤0.01% | 742 |
|
|
2021
Q3 | $92K | Buy |
775
+62
| +9% | +$7.22K | ﹤0.01% | 698 |
|
|
2021
Q2 | $84K | Sell |
713
-49
| -6% | -$5.38K | ﹤0.01% | 597 |
|
|
2021
Q1 | $75K | Buy |
762
+29
| +4% | +$2.92K | ﹤0.01% | 588 |
|
|
2020
Q4 | $73K | Buy |
733
+303
| +70% | +$32.1K | ﹤0.01% | 499 |
|
|
2020
Q3 | $46K | Buy |
430
+4
| +0.9% | +$445 | ﹤0.01% | 563 |
|
|
2020
Q2 | $45K | Sell |
426
-10
| -2% | -$1.03K | ﹤0.01% | 547 |
|
|
2020
Q1 | $38K | Sell |
436
-76
| -15% | -$7.16K | ﹤0.01% | 540 |
|
|
2019
Q4 | $50K | Sell |
512
-13
| -2% | -$1.22K | ﹤0.01% | 573 |
|
|
2019
Q3 | $46K | Buy |
525
+20
| +4% | +$1.73K | ﹤0.01% | 579 |
|
|
2019
Q2 | $41K | Sell |
505
-409
| -45% | -$32.1K | ﹤0.01% | 620 |
|
|
2019
Q1 | $73K | Sell |
914
-617
| -40% | -$48.6K | 0.01% | 453 |
|
|
2018
Q4 | $115K | Sell |
1,531
-237
| -13% | -$18.5K | 0.01% | 395 |
|
|
2018
Q3 | $139K | Sell |
1,768
-1,135
| -39% | -$85.8K | 0.01% | 409 |
|
|
2018
Q2 | $203K | Sell |
2,903
-364
| -11% | -$26.2K | 0.02% | 356 |
|
|
2018
Q1 | $234K | Buy |
3,267
+11
| +0.3% | +$762 | 0.02% | 288 |
|
|
2017
Q4 | $227K | Buy |
3,256
+20
| +0.6% | +$1.35K | 0.02% | 309 |
|
|
2017
Q3 | $220K | Hold |
3,236
| – | – | 0.02% | 301 |
|
|
2017
Q2 | $197K | Buy |
3,236
+100
| +3% | +$6.53K | 0.02% | 308 |
|
|
2017
Q1 | $190K | Sell |
3,136
-612
| -16% | -$35.6K | 0.02% | 322 |
|
|
2016
Q4 | $234K | Hold |
3,748
| – | – | 0.03% | 291 |
|
|
2016
Q3 | $234K | Buy |
3,748
+99
| +3% | +$6.47K | 0.03% | 287 |
|
|
2016
Q2 | $219K | Sell |
3,649
-631
| -15% | -$36.6K | 0.03% | 286 |
|
|
2016
Q1 | $240K | Buy |
4,280
+1,196
| +39% | +$71.9K | 0.03% | 293 |
|
|
2015
Q4 | $209K | Sell |
3,084
-312
| -9% | -$20.5K | 0.04% | 267 |
|
|
2015
Q3 | $216K | Buy |
3,396
+1,327
| +64% | +$87.3K | 0.03% | 275 |
|
|
2015
Q2 | $131K | Buy |
2,069
+545
| +36% | +$37.3K | 0.02% | 370 |
|
|
2015
Q1 | $104K | Buy |
1,524
+110
| +8% | +$7.64K | 0.02% | 412 |
|
|
2014
Q4 | $100K | Sell |
1,414
-11
| -0.8% | -$788 | 0.02% | 411 |
|
|
2014
Q3 | $101K | Hold |
1,425
| – | – | 0.02% | 403 |
|
|
2014
Q2 | $105K | Sell |
1,425
-603
| -30% | -$43.6K | 0.02% | 415 |
|
|
2014
Q1 | $130K | Buy |
2,028
+176
| +10% | +$11.4K | 0.02% | 369 |
|
|
2013
Q4 | $113K | Buy |
1,852
+391
| +27% | +$21.2K | 0.02% | 373 |
|
|
2013
Q3 | $76K | Buy |
1,461
+888
| +155% | +$44.6K | 0.01% | 398 |
|
|
2013
Q2 | $27K | Buy |
+573
| New | +$29.2K | 0.01% | 300 |
|
Other funds holding AZN
First Horizon Advisors's AZN Position: Q2 2025 in Review
First Horizon Advisors reduced its AstraZeneca (AZN) stake by 2.7% in Q2 2025, selling an estimated $13.3K and leaving 3,430 shares worth $479K. The position accounts for 0.01% of the portfolio, ranked #362.
First Horizon Advisors first reported a position in AZN in Q2 2013 and has held it in 49 quarters since. The position peaked at $518K in Q1 2025. 1,223 funds tracked by Wall St. Rank hold AZN as of Q2 2025.
- First Horizon Advisors held 3,430 shares of AstraZeneca worth $479K as of Q2 2025.
- First Horizon Advisors sold 95 AstraZeneca shares in Q2 2025, an estimated $13.3K.
- AstraZeneca made up 0.01% of First Horizon Advisors's portfolio in Q2 2025, its #362 holding.
- First Horizon Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 49 quarters since.
- First Horizon Advisors's AstraZeneca position peaked at $518K in Q1 2025.
- 1,223 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2025.
Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.